=> FILE CAPLUS
FILE 'CAPLUS' ENTERED AT 10:39:22 ON 05 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 4 Jun 2007 (20070604/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> D QUE L25
L8 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading strB.str




```
chain nodes :
7  8  9  10  11  12  13  16
ring nodes :
1  2  3  4  5  6
chain bonds :
2-7  6-8  8-9  9-10  10-11  11-12  11-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
2-7  6-8  8-9  9-10  10-11  11-12
exact bonds :
11-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Connectivity :
16:1 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:Atom  16:CLASS  17:Atom
Generic attributes :
13:
Saturation              : Unsaturated
Type of Ring System     : Monocyclic

Element Count :
Node 9: Limited
    C,C5-8

Node 13: Limited
    C,C6
```

```
L13          278 SEA FILE=REGISTRY SSS FUL L8
L14            3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13
L15          902 SEA FILE=CAPLUS ABB=ON  PLU=ON  SEKIGUCHI Y?/AU
L16           32 SEA FILE=CAPLUS ABB=ON  PLU=ON  KANUMA K?/AU
L17           21 SEA FILE=CAPLUS ABB=ON  PLU=ON  OMODERA K?/AU
L18           19 SEA FILE=CAPLUS ABB=ON  PLU=ON  BUSUJIMA T?/AU
L19         2458 SEA FILE=CAPLUS ABB=ON  PLU=ON  TRAN T?/AU
```

```
L20        9406 SEA FILE=CAPLUS ABB=ON  PLU=ON  HAN S?/AU
L21          54 SEA FILE=CAPLUS ABB=ON  PLU=ON  CASPER M?/AU
L22         757 SEA FILE=CAPLUS ABB=ON  PLU=ON  KRAMER B?/AU
L23          92 SEA FILE=CAPLUS ABB=ON  PLU=ON  SEMPLE G?/AU
L24          95 SEA FILE=CAPLUS ABB=ON  PLU=ON  ZOU N?/AU
L25           3 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L15 OR L16 OR L17 OR L18 OR
                L19 OR L20 OR L21 OR L22 OR L23 OR L24) AND L14


=> D IBIB ED ABS HITSTR 1-3 L25

L25  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:          2006:464826  CAPLUS  Full-text
DOCUMENT NUMBER:           144:488666
TITLE:                     Preparation of quinoline, tetrahydroquinazoline, and
                           pyrimidine derivatives as MCH antagonist for treatment
                           of CNS disorders
INVENTOR(S):               Sekiguchi, Yoshinori; Kanuma, Yukihiro;
                           Omodera, Katsunori; Busujima, Takeshi
                           ; Tran, Thuy-Ahn; Han, Sangdong;
                           Casper, Martin; Brian, A. Kramer; Semple,
                           Graeme; Zou, Ning
PATENT ASSIGNEE(S):        Taisho Pharmaceutical Co., Ltd., Japan; Arena
                           Pharmaceutical Inc.
SOURCE:                    Jpn. Kokai Tokkyo Koho, 781 pp.
                           CODEN: JKXXAF
DOCUMENT TYPE:             Patent
LANGUAGE:                  Japanese
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------            ----   --------    -------------------      --------
     JP 2006124387          A     20060518    JP 2005-286311           20050930
PRIORITY APPLN. INFO.:                         JP 2004-287659      A    20040930
OTHER SOURCE(S):           MARPAT 144:488666
ED   Entered STN:  19 May 2006
GI
```



AB Title compds. [I, II, III; wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide (IV)•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data).

IT **771545-17-6P 771545-22-3P 773141-41-6P**
773141-63-2P 773141-64-3P 773141-65-4P
773141-66-5P 773141-67-6P 773141-68-7P
773141-69-8P 773141-70-1P 773141-72-3P
773141-79-0P 773142-96-4P 773143-00-3P
773143-01-4P 773143-05-8P 773143-06-9P
773143-07-0P 773143-09-2P 773143-10-5P
773143-16-1P 773143-17-2P 773143-19-4P
773143-20-7P 773143-21-8P 773143-22-9P
773143-23-0P 773143-24-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

RN 771545-17-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-22-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-41-6 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-63-2 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-64-3 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-65-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-66-5 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-67-6 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-68-7 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-69-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-70-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-72-3 CAPLUS
CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3-chloro-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-79-0 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 771551-22-5
CMF C20 H25 Cl F N5 O

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 773142-96-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-00-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-01-4 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-05-8 CAPLUS
CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-06-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-07-0 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-09-2 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-10-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-

(trifluoromethyl)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-16-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-17-2 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-19-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-20-7 CAPLUS
CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-21-8 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-22-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-23-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-24-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **771544-72-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)
RN 771544-72-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **771545-85-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)
RN 771545-85-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **771543-92-1P 771543-93-2P 771543-95-4P**
771544-42-4P 771544-43-5P 771544-44-6P
771544-45-7P 771544-46-8P 771544-47-9P
771544-48-0P 771544-49-1P 771544-50-4P
771544-68-4P 771544-99-1P 771545-01-8P
771545-03-0P 771545-04-1P 771545-06-3P
771545-08-5P 771545-10-9P 771545-12-1P
771545-18-7P 771545-23-4P 771545-80-3P
771545-83-6P 771546-31-7P 771546-33-9P
771546-35-1P 771546-37-3P 771546-39-5P
771546-41-9P 771546-43-1P 771546-47-5P
771546-49-7P 771546-51-1P 771546-53-3P
771546-55-5P 771546-57-7P 771546-59-9P
771546-61-3P 771546-63-5P 771546-65-7P
771546-67-9P 771546-69-1P 771546-71-5P
771546-73-7P 771546-77-1P 771546-79-3P
771549-06-5P 771549-30-5P 771549-32-7P
771549-34-9P 771549-36-1P 771549-38-3P
771549-40-7P 771549-42-9P 771549-44-1P
771549-46-3P 771549-48-5P 771549-50-9P
771549-52-1P 771549-54-3P 771549-56-5P
771549-58-7P 771549-60-1P 771549-62-3P
771549-64-5P 771549-66-7P 771549-68-9P
771549-70-3P 771549-78-1P 771549-80-5P
771549-82-7P 771549-86-1P 771550-50-6P

771550-52-8P 771550-54-0P 771550-56-2P
771550-58-4P 771550-60-8P 771550-62-0P
771550-64-2P 771550-66-4P 771550-68-6P
771550-70-0P 771550-72-2P 771550-74-4P
771550-76-6P 771550-78-8P 771550-80-2P
771550-82-4P 771550-84-6P 771550-86-8P
771550-88-0P 771550-90-4P 771550-92-6P
771550-94-8P 771550-96-0P 771550-98-2P
771551-00-9P 771551-02-1P 771551-04-3P
771551-06-5P 771551-08-7P 771551-12-3P
771551-14-5P 771551-16-7P 771551-18-9P
771551-20-3P 771551-22-5P 771551-24-7P
771551-26-9P 771551-28-1P 771551-30-5P
771551-32-7P 771551-34-9P 771551-56-5P
771551-58-7P 771551-60-1P 771551-62-3P
771551-64-5P 771551-66-7P 771551-68-9P
771551-70-3P 771551-72-5P 771551-74-7P
771551-76-9P 771551-78-1P 771551-80-5P
771551-82-7P 771551-84-9P 771551-86-1P
771551-88-3P 771551-90-7P 771551-92-9P
771551-94-1P 771551-96-3P 771551-98-5P
771552-00-2P 771552-02-4P 771552-04-6P
771552-06-8P 771552-14-8P 771552-16-0P
771552-18-2P 771552-20-6P 771552-22-8P
771552-26-2P 771553-00-5P 771555-36-3P
771555-45-4P 771556-86-6P 771556-89-9P
771556-90-2P 771557-07-4P 771557-21-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

RN 771543-92-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771543-93-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771543-95-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771552-18-2
CMF C21 H29 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771544-42-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-43-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-44-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-45-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-46-8 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-47-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-48-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-49-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-50-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-68-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-99-1 CAPLUS
CN Benzamide, 3,5-dibromo-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771544-98-0
CMF C19 H23 Br2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-01-8 CAPLUS
CN Benzamide, 3-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-00-7
CMF C20 H23 F4 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-03-0 CAPLUS
CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-02-9
CMF C20 H24 F3 N5 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-04-1 CAPLUS
CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-06-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(ethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-05-2
CMF C20 H25 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 771545-08-5 CAPLUS
CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-[(1-methylethyl)amino]-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-07-4
CMF C21 H27 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-10-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(cyclopropylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-09-6
CMF C21 H25 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-12-1 CAPLUS
CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-11-0
CMF C19 H23 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-18-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-17-6
CMF C21 H29 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-23-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-22-3
CMF C22 H28 F3 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-80-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-83-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-31-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-33-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-35-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-37-3 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-39-5 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-41-9 CAPLUS
CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-43-1 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-47-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-49-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-51-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-53-3 CAPLUS
CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-55-5 CAPLUS
CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-57-7 CAPLUS
CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-59-9 CAPLUS
CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-61-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-63-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-65-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-67-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-69-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-71-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-73-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-77-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-

pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-79-3 CAPLUS
CN Benzamide, 3-bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771549-06-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-30-5 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-32-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-34-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-36-1 CAPLUS
CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-38-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-40-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-42-9 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-44-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-46-3 CAPLUS
CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-48-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-50-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-52-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-54-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-56-5 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-58-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-60-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-62-3 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-64-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-66-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-68-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-70-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-78-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-80-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-82-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-86-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-50-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-52-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-54-0 CAPLUS
CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-56-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-58-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-60-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-62-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-64-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-66-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-68-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-70-0 CAPLUS
CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-72-2 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-74-4 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-76-6 CAPLUS
CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-78-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-80-2 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-82-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-84-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-86-8 CAPLUS
CN Benzamide, 2-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-88-0 CAPLUS
CN Benzamide, 2-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-90-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-92-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-94-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-96-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-98-2 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-00-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-02-1 CAPLUS
CN Benzamide, 3-(dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-04-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-06-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-08-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-12-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-14-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-16-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-18-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-20-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-22-5 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-24-7 CAPLUS
CN Benzamide, 3,5-dibromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-26-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-28-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-30-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-32-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-34-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-56-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-58-7 CAPLUS
CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-60-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-62-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-64-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-66-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-68-9 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-70-3 CAPLUS
CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-72-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-74-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-76-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-78-1 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-80-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-82-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-84-9 CAPLUS
CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-86-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-88-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-90-7 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-92-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-94-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-96-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-98-5 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-00-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-02-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-04-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-06-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-14-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-16-0 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-18-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-20-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-22-8 CAPLUS
CN Benzamide, N-[4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 771552-26-2 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771553-00-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771555-36-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771555-45-4 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771556-86-6 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771556-89-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771556-90-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771557-07-4 CAPLUS
CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771557-21-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:875033 CAPLUS Full-text
DOCUMENT NUMBER: 141:332214
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): **Sekiguchi, Yoshinori; Kanuma, Kosuke ; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning**
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan
SOURCE: Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
EP 1464335 A2 20041006 EP 2004-7651 20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.: US 2003-458530P P 20030331
US 2003-495911P P 20030819
US 2003-510186P P 20031009
US 2003-530360P P 20031216
EP 2004-7651 A 20040330

ED Entered STN: 22 Oct 2004
GI



AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial

infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part III of three in a series covering the patent.

IT **771544-72-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide **771545-17-6P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771545-22-3P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **771545-85-8P**, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **773141-41-6P**, 4-Chloro-N-[cis-4-[[4-methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **773141-63-2P**, 4-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide hydrochloride **773141-64-3P**, 3-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide hydrochloride **773141-65-4P**, N-[cis-4-[(4-Dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride **773141-66-5P**, 3-Chloro-4-fluoro-N-[cis-4-[(5-methyl-4-methylaminopyrimidin-2-yl)amino]cyclohexyl]benzamide hydrochloride **773141-67-6P**, 4-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide hydrochloride **773141-68-7P**, 3-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide hydrochloride **773141-69-8P**, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride **773141-70-1P**, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-difluorobenzamide hydrochloride **773141-72-3P**, N-[cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3-chloro-4-fluorobenzamide hydrochloride **773141-79-0P**, 3-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-4-fluorobenzamide methanesulfonate **773142-96-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **773143-00-3P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **773143-01-4P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **773143-05-8P**, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **773143-06-9P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide **773143-07-0P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **773143-09-2P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **773143-10-5P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide **773143-16-1P**, 4-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide **773143-17-2P**, 3-Chloro-N-[cis-4-[(4-dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide **773143-19-4P**, N-[cis-4-[(4-Dimethylamino-6-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide **773143-20-7P**, 3-Chloro-4-fluoro-N-[cis-4-[(5-methyl-4-methylaminopyrimidin-2-yl)amino]cyclohexyl]benzamide **773143-21-8P**, 4-Chloro-N-[cis-4-[(4-dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3-fluorobenzamide **773143-22-9P**, 3-Chloro-N-[cis-4-[(4-

dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide **773143-23-0P**, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide **773143-24-1P**, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-difluorobenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as
MCH antagonist for treatment of CNS disorders)

RN 771544-72-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-17-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-22-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-85-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-41-6 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-63-2 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-64-3 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-65-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-66-5 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-67-6 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-68-7 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-69-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-70-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-72-3 CAPLUS
CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3-chloro-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-79-0 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monomethanesulfonate (9CI) (CA

INDEX NAME)

CM 1

CRN 771551-22-5
CMF C20 H25 Cl F N5 O

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 773142-96-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-00-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-01-4 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-05-8 CAPLUS
CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-06-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-07-0 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-09-2 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-10-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-16-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-17-2 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-19-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-20-7 CAPLUS
CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-21-8 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-22-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-23-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773143-24-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:875032 CAPLUS Full-text
DOCUMENT NUMBER: 141:350191
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): **Sekiguchi, Yoshinori; Kanuma, Kosuke ; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning**

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan
SOURCE: Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:

US 2003-458530P	P	20030331
US 2003-495911P	P	20030819
US 2003-510186P	P	20031009
US 2003-530360P	P	20031216
EP 2004-7651	A	20040330

ED Entered STN: 22 Oct 2004
GI





AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general

synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part II of three in a series covering the patent.

IT **771544-72-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide
771545-85-8P, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 771544-72-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-85-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **771543-92-1P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride **771543-93-2P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771543-95-4P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide trifluoroacetate **771544-42-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771544-43-5P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide **771544-44-6P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide **771544-45-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide **771544-46-8P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771544-47-9P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771544-48-0P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **771544-49-1P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **771544-50-4P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771544-68-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride **771544-99-1P**, 3,5-Dibromo-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate **771545-01-8P**, 3-Fluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-(trifluoromethyl)benzamide trifluoroacetate **771545-03-0P**, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide trifluoroacetate **771545-04-1P**, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride **771545-06-3P** **771545-08-5P**, 3,4-Difluoro-N-[cis-4-[[4-(isopropylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate **771545-10-9P** **771545-12-1P**, 3,4-Difluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate **771545-18-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate **771545-23-4P** **771545-80-3P**, N-[cis-4-[[4-(Dimethylamino)-5-ethylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **771545-83-6P**, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride **771546-31-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide hydrochloride **771546-33-9P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide hydrochloride **771546-35-1P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride **771546-37-3P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride **771546-39-5P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide hydrochloride **771546-41-9P**, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771546-43-1P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771546-47-5P**, N-[cis-4-[[4-(Dimethylamino)-5-

methylpyrimidin-2-yl]amino]cyclohexyl]-2-(methylsulfonyl)benzamide **771546-49-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(methylsulfonyl)benzamide **771546-51-1P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(methylsulfonyl)benzamide **771546-53-3P**, Methyl 2-[[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoate **771546-55-5P**, Methyl 3-[[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoate **771546-57-7P**, 2-[[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoic acid hydrochloride **771546-59-9P**, 3-[[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoic acid hydrochloride **771546-61-3P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride **771546-63-5P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride **771546-65-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride **771546-67-9P**, 3-Chloro-N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride **771546-69-1P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771546-71-5P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771546-73-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide **771546-77-1P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride **771546-79-3P**, 3-Bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771549-06-5P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide **771549-30-5P**, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-32-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771549-34-9P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-36-1P**, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-38-3P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide **771549-40-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide **771549-42-9P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-44-1P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **771549-46-3P**, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-48-5P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide **771549-50-9P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771549-52-1P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-54-3P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide **771549-56-5P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-58-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide **771549-60-1P**, N-[cis-4-[[4-

(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide **771549-62-3P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771549-64-5P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide **771549-66-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide **771549-68-9P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide **771549-70-3P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide **771549-78-1P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide **771549-80-5P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide **771549-82-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide **771549-86-1P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **771550-50-6P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **771550-52-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide **771550-54-0P**, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-56-2P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771550-58-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide **771550-60-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide **771550-62-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,5-difluorobenzamide **771550-64-2P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,3,4-trifluorobenzamide **771550-66-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-68-6P**, 4-tert-Butyl-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-70-0P**, 4-Butyl-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-72-2P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-74-4P**, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-76-6P**, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-78-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide **771550-80-2P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-82-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide **771550-84-6P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxybenzamide **771550-86-8P**, 2-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-88-0P**, 2-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-90-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-fluorobenzamide **771550-92-6P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methylbenzamide **771550-94-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)benzamide **771550-96-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide **771550-98-2P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771551-00-9P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-

ethoxybenzamide **771551-02-1P**, 3-(Dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-04-3P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide **771551-06-5P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide **771551-08-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide **771551-12-3P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide **771551-14-5P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide **771551-16-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide **771551-18-9P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide **771551-20-3P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide **771551-22-5P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771551-24-7P**, 3,5-Dibromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-26-9P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethylbenzamide **771551-28-1P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771551-30-5P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)benzamide **771551-32-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide **771551-34-9P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-56-5P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-58-7P**, 4-Butyl-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-60-1P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide **771551-62-3P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **771551-64-5P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide **771551-66-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxybenzamide **771551-68-9P**, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-70-3P**, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-72-5P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide **771551-74-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide **771551-76-9P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide **771551-78-1P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771551-80-5P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide **771551-82-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide **771551-84-9P**, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-86-1P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide **771551-88-3P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide **771551-90-7P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide

771551-92-9P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide **771551-94-1P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide **771551-96-3P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide **771551-98-5P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771552-00-2P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethylbenzamide **771552-02-4P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide **771552-04-6P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide **771552-06-8P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide **771552-14-8P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)benzamide **771552-16-0P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **771552-18-2P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771552-20-6P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trimethoxybenzamide **771552-22-8P**, N-[4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-nitrobenzamide **771552-26-2P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771553-00-5P**, 3,4-Dichloro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide **771555-36-3P**, N-[cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]-3-methoxybenzamide hydrochloride **771555-45-4P**, 3-Chloro-N-[cis-4-(4-dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride **771556-86-6P**, 3-Chloro-N-[cis-4-(4-dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride **771556-89-9P**, 3-Chloro-N-[cis-4-(4-dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride **771556-90-2P**, N-[cis-4-(4-Dimethylamino-6-ethylpyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride **771557-07-4P**, N-[cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride **771557-21-2P**, N-[cis-4-[[4-Methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines,
and pyrimidines as melanin-concentrating hormone antagonist for treatment of
CNS disorders)

RN 771543-92-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771543-93-2 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771543-95-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771552-18-2
CMF C21 H29 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771544-42-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-43-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-44-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-45-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-46-8 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-47-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-48-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-49-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-50-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-68-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771544-99-1 CAPLUS
CN Benzamide, 3,5-dibromo-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771544-98-0
CMF C19 H23 Br2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-01-8 CAPLUS
CN Benzamide, 3-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-00-7
CMF C20 H23 F4 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-03-0 CAPLUS
CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-02-9
CMF C20 H24 F3 N5 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-04-1 CAPLUS
CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771545-06-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(ethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-05-2
CMF C20 H25 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

RN 771545-08-5 CAPLUS
CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-[(1-methylethyl)amino]-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-07-4
CMF C21 H27 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-10-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(cyclopropylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-09-6
CMF C21 H25 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-12-1 CAPLUS
CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-11-0
CMF C19 H23 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-18-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-17-6
CMF C21 H29 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-23-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-22-3
CMF C22 H28 F3 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 771545-80-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-83-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-31-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-33-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-35-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride

(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-37-3 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride
(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-39-5 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, monohydrochloride
(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-41-9 CAPLUS
CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-43-1 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-47-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-49-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-51-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-53-3 CAPLUS
CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-55-5 CAPLUS
CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-57-7 CAPLUS
CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-59-9 CAPLUS
CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771546-61-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-63-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-65-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-67-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride

(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-69-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-71-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-73-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-77-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771546-79-3 CAPLUS

CN Benzamide, 3-bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-06-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-30-5 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-32-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-34-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-36-1 CAPLUS
CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-38-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-40-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-42-9 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-44-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-46-3 CAPLUS
CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-48-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-50-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-52-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-54-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-56-5 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-58-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-60-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-62-3 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-64-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-66-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-68-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-70-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-78-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-80-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-82-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771549-86-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-50-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-52-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-54-0 CAPLUS
CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-56-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-58-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-60-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-62-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 771550-64-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-66-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-68-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-70-0 CAPLUS
CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-72-2 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-74-4 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-76-6 CAPLUS
CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-78-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-80-2 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-82-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-84-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-86-8 CAPLUS
CN Benzamide, 2-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-88-0 CAPLUS
CN Benzamide, 2-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-90-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-92-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-94-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-96-0 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-98-2 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-00-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-02-1 CAPLUS
CN Benzamide, 3-(dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-04-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-06-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-08-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-12-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-14-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-16-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-18-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-20-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-22-5 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-24-7 CAPLUS
CN Benzamide, 3,5-dibromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-26-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-28-1 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-30-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-32-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-34-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-56-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-58-7 CAPLUS
CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-60-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-62-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-64-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-66-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-68-9 CAPLUS
CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-70-3 CAPLUS
CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-72-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-74-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-76-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-78-1 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-80-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-82-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-84-9 CAPLUS
CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-86-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-88-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-90-7 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-92-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-94-1 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-96-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-98-5 CAPLUS
CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-00-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-02-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-04-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-06-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-14-8 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-16-0 CAPLUS
CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-18-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-20-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-22-8 CAPLUS
CN Benzamide, N-[4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 771552-26-2 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771553-00-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771555-36-3 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771555-45-4 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771556-86-6 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771556-89-9 CAPLUS
CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771556-90-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771557-07-4 CAPLUS
CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771557-21-2 CAPLUS
CN Benzamide, N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



```
=> D QUE L14
L8                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L13          278 SEA FILE=REGISTRY SSS FUL L8
L14            3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13


=> S L14 NOT L25
L28            0 L14 NOT L25

=> FILE MARPAT
FILE 'MARPAT' ENTERED AT 10:40:40 ON 05 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 146 ISS 23 (20070601/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    2007088073 19 APR 2007
DE 102006048036 12 APR 2007
EP       1774957 18 APR 2007
JP    2007103208 19 APR 2007
WO    2007047881 26 APR 2007
GB       2430675 04 APR 2007
FR       2891841 13 APR 2007
RU       2296767 10 APR 2007
CA       2522632 06 APR 2007

Expanded G-group definition display now available.

=> D QUE L27
L8                STR
```



Structure attributes must be viewed using STN Express query preparation.
L27 24 SEA FILE=MARPAT SSS FUL L8

=> S L27 NOT L25
1 L25
L29 24 L27 NOT L25

=> D IBIB AB QHIT L29 1-24

L29 ANSWER 1 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 146:45539 MARPAT Full-text
TITLE: Preparation of aminopyridine derivatives as selective Aurora-A inhibitors for treatment of cancer
INVENTOR(S): Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi; Ohkubo, Mitsuru; Shimomura, Toshiyasu
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 151pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006129842	A1	20061207	WO 2006-JP311179	20060530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2006046734 A2 20060504 WO 2005-JP19957 20051025
WO 2006046734 A3 20060921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 2006106029 A1 20060518 US 2005-258447 20051025
PRIORITY APPLN. INFO.: JP 2005-161156 20050601
WO 2005-JP19957 20051025
JP 2004-315152 20041029
US 2005-692537P 20050621

AB The title compds. I [A1 is (RbjCRbj')m2; A2 is (RaiCRai')m1; A3 is (Y2Rc)n1CO(Y3Rd)n2R; m1 and m2 each is 1, 2, or 3; n1 and n2 each is 0 or 1; i is an integer of 1 to m1; j is an integer of 1 to m2; R is optionally substituted aryl, heteroaryl, or cycloalkyl; Rai and Rai' each is hydrogen, alkyl; Rbj and Rbj' each is hydrogen, alkyl; Rc, Rd, and R1 each is hydrogen, alkyl; X1 is CH, CX1a, N; X1a is (un)substituted alkyl; X2 is CH, N, etc.; X3 is CH, CX3a, N; X3a is (un)substituted alkyl; X4 is CH or N; Y1, Y2, and Y3 are the same or different and each is CH or N; Z1 and Z2 are the same or different and each is CH or N; and W is a 5-membered aromatic heterocycle, e.g., pyrazole or thiazole] are prepared Thus, (5-bromothiazol-2-yl)-(6-(4-benzoylpiperazin-1-ylmethyl)pyridin-2-yl)amine was prepared in a multistep process from 2-aminothiazole and 2,6-dichloropyridine. Compds. of this invention showed IC50 values of 0.36 nM to 110 nM against Aurora-A; they showed IC50 values of 47 nM to 28000 nM against Aurora-B.

MSTR 1



G1 = 11-9 13-15



G2 = CH
G3 = (1-3) 17



G5 = 20-10 21-16



G6 = NH
G9 = Ph (opt. substd. by 1 or more G23)
G10 = NH
G11 = N / 31



G12 = alkyl <containing 1-6 C> (opt. substd.)
G13 = N / 84



G26 = 2-7 4-9



Patent location: disclosure
Note: substitution is restricted
Note: or pharmaceutically acceptable salts or esters
Note: additional oxo formation also disclosed

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 2 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 146:20277 MARPAT Full-text
TITLE: Method for treating B cell regulated autoimmune disorders
INVENTOR(S): Foley, Kevin; Bertin, John; Grant, Ethan P.
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 327pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2006128172 A2 20061130 WO 2006-US20908 20060526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 2007032493 A1 20070208 US 2006-442744 20060526
PRIORITY APPLN. INFO.: US 2005-685077P 20050526

AB The invention relates to a method for treating B-cell regulated autoimmune disorders using compds. that modulate the activity of c-Rel. In the examples, it was shown that N-(3-methylbenzylidene)-N'[6-morpholin-4-yl-2- (2-pyridin-2-ylethoxy)-pyrimidin-4-yl]hydrazine inhibited the accumulation of c-Rel in the nucleus and its binding to DNA and enhanced the apoptosis of B cells.

MSTR 1

G1 = 7

G2 = N / 26

G3 = 308

G8 = NH
G13 = Me
G21 = NH
G22 = 1409



G70 = C(O)
Patent location: claim 1
Note: substitution is restricted
Note: also incorporates claims 43, 83, and 191
Note: additional substitution also claimed
Note: or pharmaceutically acceptable salts, solvates, clathrates, hydrates,, polymorphs, or prodrugs

L29 ANSWER 3 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 146:20264 MARPAT Full-text
TITLE: Method for treating cancer
INVENTOR(S): Bertin, John; Grant, Ethan P.
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 354pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006128129	A2	20061130	WO 2006-US20821	20060526

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-685056P 20050526
US 2005-720357P 20050923

AB The invention relates to a method for treating cancers using compds. that modulate the activity of c-Rel.

MSTR 1

G1 = 7

G2 = N / 26

G3 = 308

G8 = NH
G13 = Me
G21 = NH
G22 = 1409

G70 = C(O)
Patent location: claim 1
Note: substitution is restricted
Note: also incorporates claims 41, 81, and 189
Note: additional substitution also claimed
Note: or pharmaceutically acceptable salts, solvates, clathrates, hydrates, polymorphs, or prodrugs

L29 ANSWER 4 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
(ALL HITs ARE ITERATION INCOMPLETES)
ACCESSION NUMBER: 145:167276 MARPAT Full-text
TITLE: Preparation of triazolopyrimidine derivatives as serine-tyrosine and tyrosine kinases inhibitors
INVENTOR(S): Ludovici, Donald W.; Connors, Richard W.; Coats, Steven J.; Liu, Li; De Corte, Bart L.; Johnson, Dana L.; Schulz, Mark J.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076442	A2	20060720	WO 2006-US999	20060111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2007015207 A1 20070118 US 2006-329642 20060111

PRIORITY APPLN. INFO.: US 2005-644466P 20050114

AB Title compds. represented by the formula I [wherein R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (cyclo)alkyl, hydroxy, amino, etc.; R3 = aryl(alkyl), cycloalkyl, quinolinyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as serine-tyrosine and tyrosine kinases inhibitors. For example, II was provided in a multi-step synthesis starting from reaction of 3-dimethylamino-1-propanol with 1-fluoro-4-nitrobenzene. I were tested for effects on the tyrosine kinase activity of Focal Adhesion Kinase (FAK) in vitro FAK ELISA kinase assay and CAK (Cyclin Dependent Kinase Activating Kinase) assay.

MSTR 1 ITERATION INCOMPLETE



G1 = 12 / carbocycle <containing 7-11 C, aromatic, 6 normalized bonds, bicyclic, (0-1) 3-membered, (0-1) 4-membered, (0-1) 5-membered, (1-2) 6-membered, (0-1) 7-membered rings only> / heterocycle <containing 3-11 atoms, 1 or more heteroatoms, zero or more N, zero or more O, zero or more S (no other heteroatoms), aromatic, 6 or more normalized bonds, bicyclic, (0-1) 3-membered, (0-1) 4-membered, (0-1) 5-membered, (1-2) 6-membered, (0-1) 7-membered rings only> / (Specifically claimed: 231 / 286)



G2 = phenylene (opt. substd. by G3)

G3 = alkyl <containing 1-6 C> / alkoxy <containing 1-6 C> / cycloalkyl <containing 3-7 C> / OH / NH2 / alkylamino <containing 1-6 C> / dialkylamino <each alkyl containing 1-6 C> /

(Specifically claimed: OMe)

G4 = alkyl <containing 1-8 C>
(opt. substd. by (1-3) G5) / alkenyl <containing 2-8 C>
(opt. substd. by G14) / alkynyl <containing 2-8 C>
(opt. substd. by G14) / alkoxy <containing 1-8 C>
(opt. substd. by (1-3) G15) / 31 /
alkoxycarbonyl <containing 1-6 C>
(opt. substd. by (1-3) G15) / CONH2 /
alkylaminocarbonyl <containing 1-6 C> /
dialkylaminocarbonyl <each alkyl containing 1-6 C> / aryl /
tetrazolyl (opt. substd. by (1-3) alkyl <containing 1-6 C>) /
thiadiazolyl (opt. substd. by (1-3) alkyl <containing 1-6 C>
) / oxazolyl (opt. substd. by (1-3) alkyl <containing 1-6 C>
) / pyrimidinyl (opt. substd. by (1-3)
alkyl <containing 1-6 C>) / 37 / (Specifically claimed: 185 /
201 / 200 / 211 / 224 / 241 / Ph / 242 / 247 / 253 / 257 /
CONHMe / 269 / OMe / 272 / 289 / 299 / 305 / 317 / 318 /
336 / 350 / 360 / 361 / 370 / 379)













































G5 = NH2 / 14 / heterocycle <containing 1-4 heteroatoms, 1 or more N, zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, monocyclic> (opt. substd. by (1-3) G11) / 20 / 23 / alkoxycarbonyl <containing 1-6 C>



G6 = NH / 16

G7 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G8) / cycloalkyl <containing 3-7 C> (opt. substd. by (1-3) G8)

G8 = NH2 / alkylamino <containing 1-6 C> /

dialkylamino <each alkyl containing 1-6 C> /
heterocycle <containing 5-8 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N,
5- to 8-membered monocyclic ring>
(opt. substd. by (1-3) G9) / 18 / OH /
alkoxycarbonyl <containing 1-6 C> / CO2H / aryl /
heterocycle <containing 5-6 atoms, 1-3 heteroatoms, 1-2 N,
0-1 O, 0-1 S (no other heteroatoms), aromatic,
2 or more double bonds, 5- to 6-membered monocyclic ring>
(opt. substd. by (1-3) alkyl <containing 1-6 C>)

G9 = alkyl <containing 1-6 C> /
alkoxy <containing 1-6 C> / alkyl <containing 1-6 C>
(substd. by 1 or more aryl) / alkoxycarbonyl <containing 1-6
C> / CO2H / OH

G10 = heterocycle <containing 5-8 atoms,
1 or more heteroatoms, 1 or more N, zero or more O,
zero or more S (no other heteroatoms),
attached through 1 or more N, 5- to 8-membered monocyclic
ring> (opt. substd. by (1-3) G9)

G11 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more aryl) /
alkoxycarbonyl <containing 1-6 C> / CO2H / OH

G12 = heterocycle <containing 1-4 heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11)

G13 = alkyl <containing 1-6 C>

G14 = aryl / alkoxycarbonyl <containing 1-6 C>

G15 = NH2 / 27 / heterocycle <containing 1-4 heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11) / 29 / OH

G16 = NH2 / 33 / heterocycle <containing 1-4 heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11) / 35 / OH

G17 = S(O) / SO2

G18 = NH2 / alkylamino <containing 1-6 C> /
dialkylamino <each alkyl containing 1-6 C> /
heterocycle <containing 5-8 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N,

5- to 8-membered monocyclic ring>
(opt. substd. by (1-3) G9) / 39

$_3$G10=O

G19 = alkyl <containing 1-6 C> (substd. by G20) /
aryl (opt. substd. by (1-3) G21) /
cycloalkyl <containing 3-7 C> (opt. substd. by (1-3) G22) /
carbocycle <containing 7-11 C, aromatic, 6 normalized bonds,
bicyclic, (0-1) 3-membered, (0-1) 4-membered,
(0-1) 5-membered, (1-2) 6-membered,
(0-1) 7-membered rings only> (opt. substd. by 1 or more G24)
/ quinolinyl (opt. substd.) / benzothiazolyl (opt. substd.) /
benzimidazolyl (opt. substd.) / pyrazolyl (opt. substd.) /
72 / 94 / 116 / 144 / 168 / (Specifically claimed: 400 /
Ph (opt. substd. by 1 or more G28) / cyclohexyl /
2-naphthyl / cyclohexyl / 408 / 438 / 447 / 454 / 474 /
CH2Ph / 494 / 504 / cyclopentyl / 516 / 530)























G20 = aryl (opt. substd. by (1-3) G21)

G21 = alkyl <containing 1-6 C> / alkenyl <containing 2-6 C> / alkynyl <containing 2-6 C> / alkoxy <containing 1-6 C> / OH / CN / F / CO2H / cycloalkyl <containing 3-7 C> / NH2 / 42 / heterocycle <containing 1-4 heteroatoms, 1 or more N, zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, monocyclic> (opt. substd. by (1-3) G11) / 44 / 46 / alkoxycarbonyl <containing 1-6 C> / 48 / pyrimidinyl / thiadiazolyl / tetrazolyl / pyrazolyl / oxazolyl

$_{42}$G6—G7 $_{44}$G12=O $_{46}$G(O)-G16 $_{48}$G17—G18

G22 = OH / NH2 / 50 / heterocycle <containing 1-4 heteroatoms, 1 or more N, zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, monocyclic> (opt. substd. by (1-3) G11) / 52 / 54 / alkoxycarbonyl <containing 1-6 C> / CO2H / 56

$_{50}$G6—G7 $_{52}$G12=O $_{54}$G(O)-G16 $_{56}$G17—G23

G23 = NH2 / alkylamino <containing 1-6 C> / dialkylamino <each alkyl containing 1-6 C> / heterocycle <containing 5-8 atoms, 1 or more heteroatoms, 1 or more N, zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, 5- to 8-membered monocyclic ring> (opt. substd. by (1-3) G9) / 58 / alkyl <containing 1-6 C>

$_{58}$G10=O

G24 = alkyl <containing 1-6 C> / alkenyl <containing 2-6 C> / alkynyl <containing 2-6 C> / alkoxy <containing 1-6 C> / OH / CN / F / CO2H / cycloalkyl <containing 3-7 C> / NH2 / 66 / heterocycle <containing 1-4 heteroatoms, 1 or more N,

zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, monocyclic> (opt. substd. by (1-3) G11) / 60 / 62 / alkoxycarbonyl <containing 1-6 C> / 68 / pyrimidinyl / thiadiazolyl / tetrazolyl / pyrazolyl / oxazolyl

G25 = H / R
G26 = pyrrolidino / 324 / 339 / 344

G27 = OH / morpholino / pyrrolidino / 389 .

G28 = Me / OMe / F / CN
G29 = cyclohexyl / morpholino / 417 / 467 / 485

G30 = 426 / 455 / 465 / CONHMe / SO2NH2 / 489 / 532



Patent location: claim 21
Note: or pharmaceutically acceptable salts

L29 ANSWER 5 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 144:450735 MARPAT Full-text
TITLE: Preparation of novel aminopyridine derivatives having selective Aurora-A protein kinase inhibitory effect
INVENTOR(S): Ohkubo, Mitsuru; Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi; Shimomura, Toshiyasu
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046734	A2	20060504	WO 2005-JP19957	20051025
WO 2006046734	A3	20060921		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006106029	A1	20060518	US 2005-258447	20051025
WO 2006129842	A1	20061207	WO 2006-JP311179	20060530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
JP 2004-315152 20041029
JP 2005-161156 20050601
US 2005-692537P 20050621
WO 2005-JP19957 20051025

AB The title compds. (I) or pharmaceutically acceptable salts or ester thereof [wherein m1, m2 = 1, 2, 3; n1, n2 = 0, 1; i = an integer of from 1 to m1; j = an integer of from 1 to m2; R = (un)substituted aryl, heteroaryl or cycloalkyl; Rai, Rai', Rbj, Rbj', Rc, Rd, Re = H, lower alkyl; X1 = CH, CX1a, N; wherein X1a = (un)substituted lower alkyl; X2 = CH, N; X3 = CH, N, CX3a; wherein X3a = (un)substituted lower alkyl; X4 = CH, N; 1 or 2 of X1-X4 is N; Y1, Y2, Y3 = CH, N; Z1, Z2 = CH, N; W = a 5-membered aromatic heterocycle of formula Q including pyrazole or thiazole; wherein W1 = CH, N, NH, O, S; W2 = CH, CW2a, N, NW2b, O, S; wherein W2a, W2b = H, halo, cyano, C1-2 alkyl, C3-5 cycloalkyl, 1 or 2 halo-substituted C1-2 alkyl] are prepared These compds. are selective inhibitors of Aurora-A protein kinase over Aurora-B protein

kinase and exhibit synergistic anticancer activity in combination with other anticancer agents. An anticancer agent containing the compound I, and the combined use of the above anticancer agent with another anticancer agent are also disclosed. Thus, a mixture of 2.70 g 6-chloromethyl-N-(thiazol-2-yl)pyridin-2-amine, 4.00 g 1-(3-chloro-2-fluorobenzoyl)piperazine, and 6.25 mL N,N- diisopropylethylamine, and 30 mL DMF was stirred at 90° for 2 h to give, after workup and silica gel chromatog., 6-[(4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl]-N-thiazol-2-ylpyridin-2-amine (II; R = H). II (R = H) and II (R = 2-methyl-2H-tetrazol-5-yl) showed IC50 of 0.67 and 0.32 nM against Aurora-A protein kinase, resp., and 440 and 190 nM against Aurora-B protein kinase, resp. They showed IC50 of 11.00 and 0.21 μM against human cervical cancer cell (HeLa S3), resp., and also showed synergistic antiproliferative activity against HeLa S3 cells in combination with paclitaxel.

MSTR 1



G1 = 11-9 13-15

G2 = CH
G3 = (1-3) 17

G5 = 20-10 21-16

G6 = NH
G9 = Ph (opt. substd. by 1 or more G23)
G10 = NH
G11 = N / 31

G12 = alkyl <containing 1-6 C> (opt. substd.)
G13 = N / CH
G26 = 2-7 4-9

Patent location: claim 1
Note: substitution is restricted
Note: or pharmaceutically acceptable salts or esters
Note: additional oxo formation also disclosed

L29 ANSWER 6 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 144:226245 MARPAT Full-text
TITLE: N-Phenyl-2-pyrimidinamine derivatives for the treatment of immunodeficiency disease-causing viral infections
INVENTOR(S): Zeichner, Steven; Krishnan, Vyjayanthi
PATENT ASSIGNEE(S): ICES the Secretary, Department of Health and Human Serv Government of the United States, As Represented, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017353	A2	20060216	WO 2005-US24922	20050713
WO 2006017353	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-588015P 20040713

AB The invention discloses treatment of cells or humans carrying or infected with a virus capable of causing an immunodeficiency disease with particular compds., including N-phenyl-2-pyrimidinamine derivs. (Markush included), as well as medicaments comprising those compds. and uses thereof. Compds. of the invention include imatinib mesylate.

MSTR 1A



G1 = NH2
G5 = loweralkyl
G6 = phenylene (opt. substd. by 1 or more G35)
G7 = 188



G9 = NH
G11 = O
G13 = bond
G14 = 199

G17 = phenylene (opt. substd. by 1 or more G18)
G30 = NH
Patent location: claim 1
Note: or salts

MSTR 1B



G1 = NH2
G5 = loweralkyl
G6 = 492-7 493-491 494-490



G7 = 188



G9 = NH
G11 = O
G13 = bond
G14 = 199



G17 = phenylene (opt. substd. by 1 or more G18)
G30 = NH
Patent location: claim 1
Note: or salts

L29 ANSWER 7 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 143:153303 MARPAT Full-text
TITLE: A preparation of quinoline derivatives, useful as intermediates of receptor tyrosine kinase inhibitors
INVENTOR(S): Chew, Warren; Papamichelakis, Maria; Wang, Youchu
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005159446	A1	20050721	US 2005-36408	20050114
AU 2005206541	A1	20050804	AU 2005-206541	20050114
CA 2553729	A1	20050804	CA 2005-2553729	20050114
WO 2005070890	A2	20050804	WO 2005-US1384	20050114
WO 2005070890	A3	20051103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1711467	A2	20061018	EP 2005-711511	20050114

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1930128	A	20070314	CN 2005-80007748	20050114
NO 2006003501	A	20060928	NO 2006-3501	20060801
IN 2006KN02266	A	20070525	IN 2006-KN2266	20060809
PRIORITY APPLN. INFO.:			US 2004-537329P	20040116
			WO 2005-US1384	20050114

OTHER SOURCE(S): CASREACT 143:153303

AB The invention relates to a preparation of quinoline derivs. of formula I [wherein: G, R1, and R4 are independently selected from H, halogen, alkyl, alk(en/yn)yl, or hydroxymethyl, etc.; R2 is a leaving group; R3 is a protecting group; A is O, S, NH, or N(alkyl), etc.], useful as intermediates of receptor tyrosine kinase inhibitors (no biol. data). For instance, quinoline derivative II was prepared via intramol. heterocyclization of (phenylamino)propenoic acid amide III in the presence of phosphorus oxychloride.

MSTR 5

G14 = 180

G15 = 209-129 213-304

G16 = N
G17 = alkyl <containing 1-6 C> (opt. substd. by OH) / N3 / 296

G18 = 181

G21 = 265



G24 = C(O)
G28 = NH
Patent location: claim 20
Note: or salts
Note: substitution is restricted

L29 ANSWER 8 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 143:115450 MARPAT Full-text
TITLE: Preparation of phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs, useful as cognition enhancers
INVENTOR(S): Schumacher, Richard; Hopper, Allen; Dunn, Robert; Kuester, Erik; Tehim, Ashok; Renau, Thomas E.; Caroon, Joan; Talamas, Francisco; Labadie, Sharada
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061458	A2	20050707	WO 2004-US41068	20041210
WO 2005061458	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303855	A1	20050707	AU 2004-303855	20041210
CA 2548824	A1	20050707	CA 2004-2548824	20041210
US 2005222207	A1	20051006	US 2004-8775	20041210
EP 1692109	A2	20060823	EP 2004-813392	20041210
R: AT, BE, CH, LI, LV, MK, CY, AL, BG, CZ, HR				
BR 2004017110	A	20070206	BR 2004-17110	20041210
CN 1922144	A	20070228	CN 2004-80041276	20041210
JP 2007513957	T	20070531	JP 2006-543943	20041210
PRIORITY APPLN. INFO.:			US 2003-528486P	20031211
			WO 2004-US41068	20041210

AB PDE4 inhibition (no data) is achieved by novel compds., e.g., N-substituted diarylamine analogs (shown as I; variables defined below; e.g. 3-[N-[6-(cyclopropylmethoxy)-5-methoxypyridin-2-yl]-N-[(pyridin-3-

yl)methyl]amino]benzoic acid (shown as II)). For I: A, B and D are each N or CR5; R1 is halogen, alkyl having 1-4 C atoms, halogenated alkyl having 1-4 C atoms, OR6, COR6, CONR6, or NR6COR10; R2 is halogen, alkyl having 1-4 C atoms, halogenated alkyl having 1-4 C atoms, OR7, COR6, CONR6, or NR6COR10; R3 is C1-8 (un)substituted (un)branched alkyl, a partially unsatd. C5-14 carbocycle-alkyl, C7-19 arylalkyl or heteroarylalkyl group; R4 is C3-10 cycloalkyl, C6-14 aryl, heteroaryl having 5-10 ring atoms, a heterocyclic group, a heterocyclealkyl group; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, .apprx.15 example prepns. of I and intermediates are included. For example, N-(3-chlorophenyl)-N-[5-methoxy-6-[((3R)-tetrahydrofuran-3- yl)oxy]pyridin-2-yl]pyridine-3-methanamine was prepared from 6-iodo-3-methoxy-2-[((3R)-tetrahydrofuran-3-yl)oxy]pyridine and 3-chlorophenyl-N-(3-pyridylmethyl)amine.

MSTR 1



G1 = N / 10

G3 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G29) / 12



G4 = NH
G17 = Ph (opt. substd. by 1 or more G22)
G22 = 125

G24 = Ph (opt. substd.)
G26 = NH
Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: substitution is restricted
Note: also incorporates claims 2 and 3

L29 ANSWER 9 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 143:1283 MARPAT Full-text
TITLE: Materials and methods using a synergistic combination of an inhibitor of mammalian Target of Rapamycin (mTOR) and an inhibitor of Platelet-Derived Growth Factor Receptor (PDGF-R)for inhibiting neointimal hyperplasia
INVENTOR(S): Hayry, Pekka Juha
PATENT ASSIGNEE(S): Oy Helsinki Transplantation R & D Ltd., Finland
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049021	A1	20050602	WO 2004-EP12406	20041103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-517165P 20031103

AB The present invention discloses a combination of an inhibitor of a mammalian Target of Rapamycin (mTOR) and an inhibitor of a Platelet-Derived Growth Factor Receptor (PDGF-R) for treating or preventing neointimal hyperplasia. The effect is synergistic and long-lasting. In some embodiments, the mTOR inhibitor comprises rapamycin and the PDGF-R inhibitor comprises imatinib mesylate. The inhibitors may administered in a common mixture or as a sep. composition, they may also be administered in any number of different ways including orally, e.g., by pill, or locally, e.g., by means of a stent coating.

MSTR 2



G1 = NH2
G2 = loweralky1
G3 = 132

G4 = phenylene (opt. substd. by G22)
G6 = 111



G10 = Ph (opt. substd. by 1 or more G19)
G12 = O
G16 = NH
Patent location: claim 8
Note: substitution is restricted
Note: or salts

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 142:6552 MARPAT Full-text
TITLE: Preparation of pyrimidine derivatives possessing cell-cycle inhibitory activity
INVENTOR(S): Heaton, David William; Thomas, Andrew Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101564	A1	20041125	WO 2004-GB2019	20040512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636227	A1	20060322	EP 2004-732342	20040512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007500738	T	20070118	JP 2006-530484	20040512
US 2006229329	A1	20061012	US 2005-556607	20051114
PRIORITY APPLN. INFO.:			GB 2003-11274	20030516
			WO 2004-GB2019	20040512

OTHER SOURCE(S): CASREACT 142:6552
AB Title compds. I [A = carbocyclyl, heterocyclyl; R1 = halo, NO2, CN, OH, etc.; p = 0-4; R2 = sulfamoyl, etc.; q = 0-2; R3 = halo, NO2, CN, OH, CF3, etc.; n = 0-2; R4-5 = H, halo, NO2, CN, OH, etc.; m = 0-4] are prepared For instance,

2-anilino-4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3- yl)pyrimidine is prepared from 2-anilino-4-[1-(2-oxopyrrolidinyl)-2-(dimethylamino)ethenyl]pyrimidine (preparation given) and ammonium trifluoroacetate (NMP, 140°, 18 h). Selected examples have IC50 in the range of 13-42 nM for Cdk2-Cyclin E kinase. I are useful as antiproliferative agents.

MSTR 1



G1 = phenylene (opt. substd. by (1-4) G2)
G3 = 28 / 31 / 34 / 36 / 43





G4 = 74

G6 = NH
G8 = 54 / 57 / 62 / 65



G9 = C(O)
G13 = Ph (opt. substd.)
G15 = NO2 / alkyl <containing 1-3 C>
Patent location: claim 1
Note: or pharmaceutically acceptable salts or in vivo hydrolyzable esters
Note: also incorporates claim 12

MSTR 5



G1 = phenylene (opt. substd. by (1-4) G2)
G3 = 28 / 31 / 34 / 36 / 43



G4 = 74

G6 = NH
G8 = 54 / 57 / 62 / 65

G9 = C(O)
G13 = Ph (opt. substd.)
G15 = NO2 / alkyl <containing 1-3 C>
Patent location: claim 12

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 11 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 141:424210 MARPAT Full-text
TITLE: Preparation of 2-anilino-4-(imidazol-5-yl)pyrimidine derivatives and their use as cdk (cdk2) kinase inhibitors
INVENTOR(S): Thomas, Andrew Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101549	A1	20041125	WO 2004-GB2025	20040512
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1631566	A1	20060308	EP 2004-732343	20040512
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JP 2006528962	T	20061228	JP 2006-530486	20040512
US 2007037839	A1	20070215	US 2005-556561	20051114
PRIORITY APPLN. INFO.:			GB 2003-11276	20030516
			WO 2004-GB2025	20040512

AB Title compds. I [R1 = halo, NO2, CN, OH, NH2, carboxy, etc.; p = 0-4; R2 = sulfamoyl, etc.; q = 0-2; R3 = halo, NO2, CN, OH, CF3, etc.; n = 0-2; R4 = H, alk(en/yn)yl, cycloalkyl, etc.; R5 = H, halo, NO2, CN, etc.; R6 = H, alkyl, cycloalkyl, Ph, etc.] are prepared For instance, 2-Anilino-4-[1-isopropy1-2-(N-hydroxyiminomethyl)imidazol-5-yl]pyrimidine is prepared from the corresponding aldehyde and hydroxylamine. Selected compds. of the invention exhibit IC50 in the range of 1 mM to 1 nM for CDK2 kinase. I are useful for producing a cell cycle inhibitory (anti cell proliferation) effect.

MSTR 1



G1 = phenylene (opt. substd. by (1-4) G2)
G3 = 28 / 31 / 34 / 36 / 43



G4 = 74

G6 = NH
G8 = 54 / 57 / 62 / 65

G9 = C(O)
G13 = Ph (opt. substd.)
G15 = NO2 / alkyl <containing 1-3 C>
Patent location: claim 1
Note: or pharmaceutically acceptable salts or in vivo hydrolyzable esters
Note: also incorporates claim 12

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 12 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 141:314346 MARPAT Full-text
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan; Arena Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1464335	A2	20041006	EP 2004-7651	20040330
EP 1464335	A3	20070509		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005197350	A1	20050908	US 2004-812075	20040330
AU 2004226049	A1	20041014	AU 2004-226049	20040331
CA 2518913	A1	20041014	CA 2004-2518913	20040331
WO 2004087669	A1	20041014	WO 2004-JP4624	20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

JP 2004300156	A	20041028	JP 2004-107965	20040331
BR 2004008910	A	20060321	BR 2004-8910	20040331
CN 1798736	A	20060705	CN 2004-80014547	20040331
IN 2005KN01805	A	20061201	IN 2005-KN1805	20050912
NO 2005004999	A	20051107	NO 2005-4999	20051027

PRIORITY APPLN. INFO.: US 2003-458530P 20030331
US 2003-495911P 20030819
US 2003-510186P 20031009
US 2003-530360P 20031216
WO 2004-JP4624 20040331

AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part I of three in a series covering the patent.

MSTR 1C

G1 = 32-5 34-2

G6 = alkyl <containing 1-5 C>
(opt. substd. by 1 or more G3)
G7 = 58-1 61-3 / 123-1 125-3



G8 = NH
G10 = 66-58 69-60

G12 = 121

G13 = O
G16 = m-C6H4Me
G36 = NH2
Patent location: claim 1
Note: substitution is restricted
Note: additional substitution also claimed

L29 ANSWER 13 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 141:38625 MARPAT Full-text
TITLE: Preparation of Chk-, pdk- and akt-inhibitory pyrimidines
INVENTOR(S): Bryant, Judi; Kochanny, Monica; Yuan, Shendong; Khim, Seock-Kuy; Buckman, Brad; Arnaiz, Damian; Boemer, Ulf; Briem, Hans; Esperling, Peter; Huwe, Christoph; Kuhnke, Joachim; Schaefer, Martina; Wortmann, Lars; Kosemund, Dirk; Eckle, Emil; Feldman, Richard; Phillips, Gary
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048343	A1	20040610	WO 2003-EP13443	20031128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502970	A1	20040610	CA 2003-2502970	20031128
AU 2003288198	A1	20040618	AU 2003-288198	20031128
US 2004186118	A1	20040923	US 2003-722591	20031128
EP 1565446	A1	20050824	EP 2003-780086	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016680	A	20051018	BR 2003-16680	20031128
CN 1717396	A	20060104	CN 2003-80104544	20031128
JP 2006508997	T	20060316	JP 2004-554522	20031128
IN 2005DN01603	A	20070202	IN 2005-DN1603	20050420
NO 2005003144	A	20050627	NO 2005-3144	20050627
PRIORITY APPLN. INFO.:			EP 2002-26607	20021128
			WO 2003-EP13443	20031128

AB The title compds. [I; A, B = CN, halo, H, OH, etc.; X = O, (un)substituted NH; R1 = H, halo, CH2OH, alkyl, etc.; R2 = H, (un)substituted NHCO-aryl or alkyl] which are inhibitors of kinases useful as medications for treating various diseases, were prepared E.g., a multi-step synthesis of 5-bromo-4-[2-(1H-imidazol-4-yl)ethylamino]-2-(4-pyrrolidin-1- ylmethylphenylamino)pyrimidine, starting from 5-bromouracil, was given. Biol. data for inhibition of Akt-2, Chk-1, and VEGFR-II (KDR) were given. The pharmaceutical composition comprising the compds. I is claimed.

MSTR 1



G1 = 302

G25 = alkyl <containing 1-6 C>

G28 = 136

G42 = 266-7 267-10 268-9

G43 = Ph
Patent location: claim 1
Note: and isotopes, solvates, polymorphs, or pharmaceutically acceptable salts
Note: additional oxo group substitution and ring formation also claimed
Stereochemistry: or diastereomers or enantiomers

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 14 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 137:201334 MARPAT Full-text
TITLE: Preparation of N-phenyl 4-heterocyclylpyrimidin-2-amines for inhibition of cell-proliferation
INVENTOR(S): Thomas, Andrew Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066481	A1	20020829	WO 2002-GB603	20020212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438646	A1	20020829	CA 2002-2438646	20020212
AU 2002231960	A1	20020904	AU 2002-231960	20020212
EP 1362050	A1	20031119	EP 2002-712053	20020212
EP 1362050	B1	20050202		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

BR 2002007294	A	20040302	BR 2002-7294	20020212
JP 2004521916	T	20040722	JP 2002-565995	20020212
CN 1524081	A	20040825	CN 2002-808167	20020212
AT 288436	T	20050215	AT 2002-712053	20020212
NZ 527367	A	20050429	NZ 2002-527367	20020212
PT 1362050	T	20050531	PT 2002-712053	20020212
ES 2236494	T3	20050716	ES 2002-2712053	20020212
ZA 2003006081	A	20041117	ZA 2003-6081	20030806
US 2004097506	A1	20040520	US 2003-467886	20030813
US 6844341	B2	20050118		
NO 2003003635	A	20030815	NO 2003-3635	20030815
PRIORITY APPLN. INFO.:			GB 2001-3926	20010217
			WO 2002-GB603	20020212

AB The title compds. [I; ring A = (un)substituted imidazo[1,2-a]pyrazin-3-yl, imidazo[1,2-a]pyrimidin-3-yl, imidazo[1,2-b]pyridazin-3-yl, etc.; R1 = halo, NO2, CN, etc.; n = 0-2; R3 = halo, NO2, CN, etc.; p = 0-4; R4 = EB; B = (un)substituted alkyl, Ph, heterocyclyl, etc.; E = a direct bond, O, CO, etc.; q = 0-2], useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-quest-blooded animal, such as man, were prepared and formulated. Thus, treating 2-anilino-4-(imidazo[1,2-b]pyridazin-3-yl)pyrimidine (preparation given) dissolved in thionyl chloride, with chlorosulfonic acid, followed by reaction of the intermediate with methanolic ammonia afforded 64% I [A = imidazo[1,2-b]pyridazin-3-yl; R1, R3 = H; R4 = 4-sulfamoyl]. In general, cyclin E/CDK2 activity possessed by compds. I may be demonstrated at IC50's in range 250 μM to 1 nM.

MSTR 1

G6—G13

G1 = NO2 / alkyl <containing 1-6 C> (opt. substd.)
G4 = 69



G6 = 7

G13 = Ph (opt. substd. by (1-5) G14)
G14 = (0-2) G4

G15 = Ph (opt. substd.)
Patent location: claim 1
Note: or pharmaceutically acceptable salts or hydrolysable esters
Note: also incorporates claim 14, formulas III, IV, VI, and IX

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 15 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 137:201324 MARPAT Full-text
TITLE: Preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylaminopyrimidines for the treatment of GSK3-related disorders
INVENTOR(S): Berg, Stefan; Bhat, Ratan; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066480	A2	20020829	WO 2002-SE270	20020218
WO 2002066480	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2435177	A1	20020829	CA 2002-2435177	20020218
AU 2002232346	A1	20020904	AU 2002-232346	20020218
BR 2002007096	A	20040120	BR 2002-7096	20020218
EP 1423388	A2	20040602	EP 2002-712572	20020218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522777	T	20040729	JP 2002-565994	20020218
NZ 527009	A	20060428	NZ 2002-527009	20020218
CN 1823064	A	20060823	CN 2002-805252	20020218
ZA 2003006175	A	20041108	ZA 2003-6175	20030808
NO 2003003677	A	20031002	NO 2003-3677	20030819
US 2004106574	A1	20040603	US 2003-468605	20030819
US 7078410	B2	20060718		
PRIORITY APPLN. INFO.:			US 2001-269903P	20010220
			WO 2002-SE270	20020218

AB The title compds. [I; ring A = imidazo[1,2-a]pyrid-3-yl or pyrazolo[2,3-a]pyrid-3-yl; R2 = halo, NO2, CN, etc.; m = 0-5; R1 = halo, NO2, CN, etc.; n = 0-2; ring B = Ph, Ph fused to cycloalkyl; R3 = halo, NO2, CN, etc.; p = 0-4; R4 = EA (A = H, alkyl, Ph, etc.; E = a direct bond, O, CO, etc.); q = 0-2], useful in the treatment and/or prophylaxis of conditions associated with glycogen synthase kinase-3, were prepared and formulated. Thus, reacting 3-chloroaniline with 4-(2-methylimidazo[1,2- a]pyrid-3-yl)-2-

methylthiopyrimidine (preparation given) in the presence of NaH in NMP afforded 21% II. Typical Ki values for the compds. I are in the range of about 0.001 to about 10,100 nM in human GSK3β assay.

MSTR 1



G4 = NO2 / alkyl <containing 1 or more C>
(opt. substd.)
G6 = 50

G9 = 93

G17 = 95-50 96-94

G18 = NH
G19 = Ph (opt. substd.)
G20 = phenylene (opt. substd. by 1 or more G7)
Patent location: claim 1
Note: or pharmaceutically acceptable salts

L29 ANSWER 16 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 136:247599 MARPAT Full-text
TITLE: Preparation of imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
INVENTOR(S): Breault, Gloria Anne; Newcombe, Nicholas John; Thomas, Andrew Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020512	A1	20020314	WO 2001-GB3864	20010830
WO 2002020512	A9	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417148	A1	20020314	CA 2001-2417148	20010830
AU 200184192	A	20020322	AU 2001-84192	20010830
BR 2001013496	A	20030701	BR 2001-13496	20010830
EP 1351958	A1	20031015	EP 2001-963159	20010830
EP 1351958	B1	20040616		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200302922	A2	20031229	HU 2003-2922	20010830
HU 200302922	A3	20070228		
JP 2004508365	T	20040318	JP 2002-525133	20010830
JP 3523641	B2	20040426		
AT 269327	T	20040715	AT 2001-963159	20010830
NZ 523787	A	20040924	NZ 2001-523787	20010830
PT 1351958	T	20040930	PT 2001-963159	20010830
ES 2221904	T3	20050116	ES 2001-1963159	20010830
EE 200300088	A	20050215	EE 2003-88	20010830
RU 2284327	C2	20060927	RU 2003-109612	20010830
TW 242559	B	20051101	TW 2001-90122494	20010911
ZA 2003000612	A	20040422	ZA 2003-612	20030122
BG 107579	A	20031031	BG 2003-107579	20030221
NO 2003001006	A	20030304	NO 2003-1006	20030304
US 2004014776	A1	20040122	US 2003-363655	20030304
US 6969714	B2	20051129		
HK 1057553	A1	20041231	HK 2004-100403	20040119
US 2006004033	A1	20060105	US 2005-169197	20050629
PRIORITY APPLN. INFO.:			GB 2000-21726	20000905
			WO 2001-GB3864	20010830
			US 2003-363655	20030304

AB Title compds. I [R1 = halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, alk(en/yn)yl, alkoxy; p = 0-4; R2 = sulfamoyl, Ra-Rb; q = 0-2; p + q = 0-5; R3 = halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alk(en/yn)yl, alkoxy, alkanoyl, etc.; n = 0-2, R4 = H, alk(en/yn)yl, cycloalkyl, Ph, etc.; R5-6 = H, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alk(en/yn)yl, alkoxy, etc.; Ra = alk(en/yn)yl, cycloalkyl, Ph, heterocyclyl, phenyl-alkyl, etc.; Rb = C(O), amido, carboxamido, etc.] were prepared For instance, phenylguanidine hydrogen carbonate was condensed with 5-(3-dimethylaminoprop-2-en-1-oyl)-1-methylimidazole (i-PrOH, NaOMe, reflux, 3 h) to give II in 64% yield. The CDK2 inhibitory activity of II was measured as IC50 = 0.146 μM.

MSTR 1



G1 = Ph (opt. substd. by 1 or more G2)
G2 = (up to 2) G4
G4 = 11 / 13 / 18



G5 = Ph (opt. substd.)
G7 = NH
G8 = C(O)
G12 = NO2 / alkyl <containing 1 or more C>
(opt. substd.)
Patent location: claim 1
Note: or pharmaceutically acceptable salts or in vivo hydrolysable esters

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 17 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 134:193444 MARPAT Full-text
TITLE: Preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases.
INVENTOR(S): Thomas, Andrew Peter; Breault, Gloria Anne; Beattie, John Franklin; Jewsbury, Phillip John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014375	A1	20010301	WO 2000-GB3139	20000815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2376293	A1	20010301	CA 2000-2376293	20000815
BR 2000013476	A	20020430	BR 2000-13476	20000815

EP 1214318	A1	20020619	EP 2000-953319	20000815
EP 1214318	B1	20031008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 200202494	A2	20021028	HU 2002-2494	20000815
JP 2003507478	T	20030225	JP 2001-518706	20000815
AU 757639	B2	20030227	AU 2000-65833	20000815
EE 200200080	A	20030616	EE 2002-80	20000815
AT 251623	T	20031015	AT 2000-953319	20000815
PT 1214318	T	20040227	PT 2000-953319	20000815
ES 2208397	T3	20040616	ES 2000-953319	20000815
NZ 516740	A	20040924	NZ 2000-516740	20000815
RU 2248976	C2	20050327	RU 2002-107128	20000815
ZA 2002000028	A	20030402	ZA 2002-28	20020102
IN 2002MN00027	A	20050318	IN 2002-MN27	20020109
BG 106383	A	20020930	BG 2002-106383	20020204
NO 2002000832	A	20020412	NO 2002-832	20020220
NO 322818	B1	20061211		
US 6855719	B1	20050215	US 2002-69019	20020221
HK 1045510	A1	20040319	HK 2002-107002	20020925
PRIORITY APPLN. INFO.:			GB 1999-19778	19990821
			WO 2000-GB3139	20000815

AB Title compds. [I; A = imidazo[1,2a]pyrid-3-yl, pyrazolo[2,3a]pyrid-3-yl; R1 = halo, NO2, cyano, OH, CF3, OCF3, amino, CO2H, sulfamoyl, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, Ph, heterocyclyl, etc.; R2 = halo, NO2, cyano, OH, CF3, OCF3, amino, CO2H, SH, carbamoyl, sulfamoyl, (substituted) alkyl, alkenyl, alkynyl, alkoxyl, Ph, heterocyclyl, PhS, etc.; R3 = halo, NO2, cyano, OH, amino, CO2H, carbamoyl, SH, sulfamoyl, alkenyl, alkynyl; m = 0-5; n = 0-2; Ring B = Ph or Ph fused to a C5-7 cycloalkyl ring; p = 0-4; R4 = AE; A = (substituted) alkyl, Ph, heterocyclyl, cycloalkyl, phenylalkyl, heterocyclylalkyl, cycloalkylcycloalkyl; E = bond, O, CO, CO2, NRaCO, NRa, S, SO, SO2, SO2NRa; q = 0-2; p+q≤5], were prepared Thus, NaH was added to 3-chloroaniline in N-methylpyrrolidone; after 30 min. 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-methylthiopyrimidine (preparation given) in N-methylpyrrolidone was added and the mixture was heated at 150° for 3 h to give 21% 2-(3-chloroanilino)-4-(2-methylimidazo[1,2-a]pyrid-3- yl)pyrimidine. 2-[4-(2-Diethylaminoethoxy)anilino]-4-(imidazo[1,2-a]pyrid- 3-yl)pyrimidine showed CDK2 inhibitory activity with IC50 = 0.17 μM.

MSTR 1



G1 = NO2 / alkyl <containing 1 or more C> (opt. substd.)
G6 = Ph (opt. substd. by (1-4) G7)
G7 = (up to 2) G9
G9 = 59



G14 = Ph (opt. substd.)
G15 = NH
Patent location: claim 1
Note: or pharmaceutically acceptable salts or in vivo hydrolysable esters

MSTR 3

G20—G6

G1 = NO2 / alkyl <containing 1 or more C> (opt. substd.)
G6 = Ph (opt. substd. by (1-4) G7)
G7 = (up to 2) G9
G9 = 59

G15—C(O)-G14

G14 = Ph (opt. substd.)
G15 = NH
G20 = 7

Patent location: claim 9

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 18 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 132:347593 MARPAT Full-text
TITLE: Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural fungicides
INVENTOR(S): Shibata, Masaru; Kawai, Kiyoshi; Makihara, Takechi; Yonekura, Norihisa; Kawashima, Takahiro; Sakai, Junetsu; Muramatsu, Norimichi
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000029404	A1	20000525	WO 1999-JP6364	19991115
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000212181	A	20000802	JP 1999-322069	19991112
CA 2350968	A1	20000525	CA 1999-2350968	19991115
BR 9915401	A	20010814	BR 1999-15401	19991115
EP 1132387	A1	20010912	EP 1999-972212	19991115
EP 1132387	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 200104171	A2	20020228	HU 2001-4171	19991115
TR 200101381	T2	20020521	TR 2001-20010138	19991115
AU 755538	B2	20021212	AU 2000-11805	19991115
RU 2222536	C2	20040127	RU 2001-116600	19991115
AT 305465	T	20051015	AT 1999-972212	19991115
JP 2000302780	A	20001031	JP 2000-38498	20000216
JP 3820337	B2	20060913		
US 6576631	B1	20030610	US 2001-830578	20010508
ZA 2001003758	A	20020319	ZA 2001-3758	20010509
US 2004023966	A1	20040205	US 2003-383693	20030310
US 6872729	B2	20050329		
PRIORITY APPLN. INFO.:			JP 1998-343614	19981117
			JP 1999-39566	19990218
			WO 1999-JP6364	19991115
			US 2001-830578	20010508

AB Title compds. I (A = N, CR3; R1, R2 = H, halo, alkyl, alkenyl, etc.; R3 = H, alkyl, alkoxy, halo; X = H, halo, nitro, cyano, etc.; Y = halo, nitro, cyano, alkyl, etc.; n = 0, 1 ,2, 3), useful as agricultural/horticultural fungicides, are prepared Thus, reaction of benzimidazole with 2-chloro-4-methoxypyrimidine in DMF in the presence of NaH gave 1-(4-methoxypyrimidin-2-yl)benzimidazole (II). II at 500 ppm gave >80% control against Erysiphe graminis on barley seedlings.

MSTR 2



G1 = 16

G2 = alkyl <containing 1-6 C>
G3 = dialkylamino <each alkyl containing 1-4 C>
G7 = Ph (opt. substd. by 1 or more G6)
G9 = 30

Patent location: claim 6
Note: substitution is restricted

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 19 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 132:44977 MARPAT Full-text
TITLE: Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anticoagulants
INVENTOR(S): Kochanny, Monica; Morrissey, Michael M.; Ng, Howard P.
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA
SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 713,066.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6008234	A	19991228	US 1997-920319	19970827
CA 2264521	A1	19980319	CA 1997-2264521	19970911
WO 9811094	A1	19980319	WO 1997-EP4961	19970911
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9743843	A	19980402	AU 1997-43843	19970911
AU 723999	B2	20000907		
EP 929547	A1	19990721	EP 1997-942015	19970911
EP 929547	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1234798	A	19991110	CN 1997-198664	19970911
HU 9903184	A2	20000228	HU 1999-3184	19970911
HU 9903184	A3	20010628		
JP 2001500147	T	20010109	JP 1998-513257	19970911
JP 3565864	B2	20040915		

AT 228513	T	20021215	AT 1997-942015	19970911
PT 929547	T	20030331	PT 1997-942015	19970911
ES 2188979	T3	20030701	ES 1997-942015	19970911
KR 2000036017	A	20000626	KR 1999-701989	19990310
NO 9901206	A	19990511	NO 1999-1206	19990311
MX 9902396	A	20000331	MX 1999-2396	19990311
US 6177473	B1	20010123	US 1999-439065	19991112
US 6232325	B1	20010515	US 1999-438354	19991112
US 6265404	B1	20010724	US 1999-438270	19991112
CN 1338454	A	20020306	CN 2001-121736	20010703
PRIORITY APPLN. INFO.:			US 1996-713066	19960912
			US 1997-920319	19970827
			WO 1997-EP4961	19970911

AB Benzamidine derivs. substituted by cyclic amino acid and cyclic hydroxy acid derivs. are provided which are useful as anticoagulants. Also disclosed are pharmaceutical compns. containing the compds. of the invention, and methods of using the compds. to treat disease-states characterized by thrombotic activity.

MSTR 1



G1 = 11

G2 = Ph
G8 = 37

G15 = 59-7 58-45 57-23

G23 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G18)
G26 = 255



G27 = NH
G41 = (1) N / 294

Derivative: and pharmaceutically acceptable salts
Patent location: claim 1
Stereochemistry: or stereoisomers or salts

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 20 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 131:37806 MARPAT Full-text
TITLE: Pyrimidine compound dye and thermal-transfer printing material and ink-jet printing liquid using same
INVENTOR(S): Ohya, Hidenobu; Kida, Shuji; Kaneko, Manabu
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11152417	A	19990608	JP 1997-336535	19971120

PRIORITY APPLN. INFO.: JP 1997-336535 19971120

AB The title dye has the general formula B:DA [A = pyrimidine ring having at least NR1R2 as a substituent, A links to D at the C atom in the pyrimidine ring; B = coupler component which links to D at its active point; D = N or CH; R1, R2 = H, (substituted) alkyl, (substituted) aryl, (substituted) heterocycle, R1 and R2 may link each other to form a ring]. A thermal-transfer printing material possessing a layer containing the dye on a support and an ink-jet printing liquid containing the dye are also claimed. The material and the printing liquid produce light-fast images.

MSTR 1

G1 = 5-2 7-4

G2 = NH2
G4 = 141



G5 = N
G6 = Me
G18 = Ph
Patent location: claim 1

L29 ANSWER 21 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 128:230376 MARPAT Full-text
TITLE: Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives, and their use as anticoagulants
INVENTOR(S): Kochanny, Monica; Morrissey, Michael M.; Ng, Howard P.
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811094	A1	19980319	WO 1997-EP4961	19970911
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6008234	A	19991228	US 1997-920319	19970827
CA 2264521	A1	19980319	CA 1997-2264521	19970911
AU 9743843	A	19980402	AU 1997-43843	19970911
AU 723999	B2	20000907		
EP 929547	A1	19990721	EP 1997-942015	19970911
EP 929547	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2001500147	T	20010109	JP 1998-513257	19970911
JP 3565864	B2	20040915		
AT 228513	T	20021215	AT 1997-942015	19970911
NO 9901206	A	19990511	NO 1999-1206	19990311
MX 9902396	A	20000331	MX 1999-2396	19990311
PRIORITY APPLN. INFO.:			US 1996-713066	19960912
			US 1997-920319	19970827
			WO 1997-EP4961	19970911

AB The invention is directed to benzamidine derivs. substituted by cyclic amino acid and cyclic hydroxy acid derivs., which are represented by seven general formulas, e.g., I [A = CR8 or N; Z1, Z2 = O, NR9, S, S(O), S(O)2, or OCH2; R1, R4 = H, halo, alkyl, NO2, OR9, CO2R9, NR9R10 or derivs.; R2 = C(:NH)NH2, C(:NH)NHOR9, C(:NH)NHCO2R12, C(:NH)NHCOR9, etc.; R3 = H, alkyl, halo, haloalkyl, NO2, ureido, guanidino, OR9, C(:NH)NH2 or derivs., etc.; R5, R6 = H, halo, alkyl, haloalkyl, NR9R10, CO2R9, etc.; R7 = NR9(CR9R10)0-4R13, O(CR9R10)0-4R13, or NR14R15; R8 = H, alkyl, halo; R9, R10 = H, alkyl, (un)substituted aryl or aralkyl; R12 = alkyl, (un)substituted aryl or aralkyl; R13 = (un)substituted carbocycle; R13, NR14R15 = (un)substituted heterocycle]. The compds. are useful as anticoagulants. This invention is also directed to pharmaceutical compns. containing the compds., and their use to treat thrombotic disease states. For example, pentafluoropyridine underwent a sequence of: (1) amination in the 4-position by Et 1-amino-1-cyclopentanecarboxylate-HCl (82%); (2) N-methylation of the amino group (65%); (3) etherification in the 2-position with 2-(benzyloxy)-5-cyanophenol (60%); (4) etherification in the 6-position with 3-(1-methylimidazolin-2-yl)phenol; and (5) Pinner reaction of the nitrile with concomitant debenzylation, to give title compound II (isolated as the CF3CO2H salt).

MSTR 1



G1 = 10-3 12-5 14-8

G2 = 15 / N

G3 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G8)
G4 = Ph

G12 = 72

G14 = 90-3 89-84 88-1

G16 = 215

G17 = 220

G24 = 268-4 274-259

G31 = 289

Derivative: or pharmaceutically acceptable salts
Patent location: claim 1
Note: substitution is restricted
Stereochemistry: single stereoisomer or mixture

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 22 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 119:273400 MARPAT Full-text
TITLE: Continuous reaction of halopyrimidines with amines
INVENTOR(S): Arnold, Siegbert; Frosch, Hans Georg; Hoppe, Manfred; Muellers, Wolfgang; Sommer, Richard

PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 542079	A2	19930519	EP 1992-118736	19921102
EP 542079	A3	19940817		
EP 542079	B1	19970723		
R: CH, DE, FR, GB, LI				
DE 4137291	A1	19930519	DE 1991-4137291	19911113
JP 05222306	A	19930831	JP 1992-321425	19921106
US 5420255	A	19950530	US 1994-200865	19940222
PRIORITY APPLN. INFO.:			DE 1991-4137291	19911113
			US 1992-970897	19921103

AB Reactive dyes are obtained by continuous condensation of halopyrimidines with aqueous amine solns. or dispersions using sep. feeding of the reactants, and removal of the product; the reactants are simultaneously added to the reactor with intensive stirring, e.g., at Reynolds number ≥2500. Thus, 9 kg/h 5-chloro-2,4,6-trifluoropyrimidine (I) at 20° and 171 L/h aqueous solution at 40° containing 12.9 kg Na 7-amino-4-hydroxy-2- naphthalenesulfonate and 2.1 kg NaF were introduced (with I pressure drop 35 bars) to a jet nozzle reactor and the product at 0° was coupled with diazotized 2-amino-5-methoxybenzenesulfonic acid to give an azo dye. The dye provided clear scarlet shades on cotton.

MSTR 3A



G1 = 757-1 758-3 / 759-1 761-3 / 762-1 764-3 /
765-1 766-3 / 767-1 769-3



G3 = Ph (opt. substd. by 1 or more G4)
G5 = pyrimidinyl (substd. by 1 or more G6)
G6 = NO2 / Me
G17 = NH
G52 = C(O)
G55 = phenylene (opt. substd. by (up to 2) SO3H)
Patent location: claim 5

MSTR 1

G5—G7

Patent location: claim 5

MSTR 3A



G1 = 757-1 758-3 / 759-1 761-3 / 762-1 764-3 /
765-1 766-3 / 767-1 769-3



G3 = Ph (opt. substd. by 1 or more G4)
G5 = pyrimidinyl (substd. by 1 or more G6)
G6 = NO2 / Me
G17 = NH
G52 = C(O)
G55 = phenylene (opt. substd. by (up to 2) SO3H)
Patent location: claim 5

MSTR 3B



G1 = 757-1 758-3 / 759-1 761-3 / 762-1 764-3 /
765-1 766-3 / 767-1 769-3



G3 = 912



G5 = pyrimidinyl (substd. by 1 or more G6)
G6 = NO2 / Me
G17 = NH
G52 = C(O)
G55 = phenylene (opt. substd. by (up to 2) 1043)



Patent location: claim 5

L29 ANSWER 23 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 119:37437 MARPAT Full-text
TITLE: Silver halide photographic material
INVENTOR(S): Kato, Takashi; Hioki, Takanori; Ikeda, Tadashi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 103 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 532042	A1	19930317	EP 1992-115605	19920911
EP 532042	B1	19991222		
R: DE, GB, NL				
JP 05072662	A	19930326	JP 1991-261389	19910913
US 5489505	A	19960206	US 1995-397725	19950302
PRIORITY APPLN. INFO.:			JP 1991-261389	19910913
			US 1992-943674	19920911
			US 1993-150793	19931112

AB The title photog. material contains a special bridge group-bearing cyanine dye I [Z1, Z2 = atoms necessary to form 5- or 6-membered N-containing ring; Q = atoms necessary to form 5- or 6-membered ring; R1 = alkyl, aryl, heterocyclyl; R2, R3 = alkyl; L1-L6 = methine group; m, n = 0, 1; M = ion necessary to

neutralize elec. charge; p = number necessary to neutralize elec. charge]. The photog. material has high sensitivity and excellent storage stability.

MSTR 2



G1 = 25-1 47-3



G6 = CH / 1 or more N
G8 = alkyl / 187

Patent location: claim 8

L29 ANSWER 24 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 117:58797 MARPAT Full-text
TITLE: Silver halide emulsion
INVENTOR(S): Hioki, Takanori; Matsunaga, Atsushi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 146 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 474047	A1	19920311	EP 1991-114082	19910822
EP 474047	B1	19960612		
R: DE, FR, GB, IT, NL				
JP 04104138	A	19920406	JP 1990-221780	19900823
JP 04104139	A	19920406	JP 1990-221783	19900823
JP 2767490	B2	19980618		
US 5223389	A	19930629	US 1991-748600	19910822
EP 647878	A2	19950412	EP 1994-120560	19910822
EP 647878	A3	19970730		

EP 647878 B1 20000112
R: DE, FR, GB, IT, NL
PRIORITY APPLN. INFO.: JP 1990-221780 19900823
JP 1990-221783 19900823
EP 1991-114082 19910822

AB A photog. emulsion comprises ≥1 methine dye represented by the general formula (MET)p[QrAr]s [MET = an atomic group having a methine dye structure; Q = a divalent linking group; p = 1, 2; r = 1-4; q = 0, 1; Ar = an aromatic polycyclic group formed of ≥8 atoms containing ≥1 N atom, with the proviso that the N atom is in a form such that tautomerism does not produce -NH-. A photog. material is also claimed which contains a photog. emulsion layer comprising Ag halide grains containing Fe ions in an amount of 10-7-10-3 mol/mol Ag halide and having a localized phase with an Fe ion concentration ≥10 times that of the other portions. The photog. material exhibits a blue sensitivity difference of ≤0.1 between when it is developed after exposure in vacuum under 10-5 torr and when it is developed after exposure in air under 760 torr. The material shows reduced fluctuation of sensitivity during storage.

MSTR 2



G1 = 42-7 67-9 / 67-7 42-9



G2 = alkyl (opt. substd.) / NH2
G5 = 1 or more N / CH
Patent location: claim 3

Search History

```
L1            1 SEA ABB=ON  PLU=ON  US2004-812075/APPS

     FILE 'REGISTRY' ENTERED AT 09:48:18 ON 05 JUN 2007
L2            7 SEA ABB=ON  PLU=ON  (769192-99-6 OR 769193-00-2 OR 769193-01-3
                OR  769193-02-4 OR 769193-03-5 OR  769193-04-6 OR 769193-05-7)/
                RN
L3            1 SEA ABB=ON  PLU=ON  769190-72-9/RN


     FILE 'CAPLUS' ENTERED AT 09:50:30 ON 05 JUN 2007
L4              ANALYZE PLU=ON  L1 1- RN :    1738 TERMS

     FILE 'REGISTRY' ENTERED AT 09:53:14 ON 05 JUN 2007
L5            8 SEA ABB=ON  PLU=ON  (769190-72-9 OR 1655-07-8 OR 175278-12-3
                OR 220996-80-5 OR 223131-01-9 OR 23631-02-9 OR 247570-24-7 OR
                31058-81-8)/RN
L6              STRUCTURE UPLOADED
L7            2 SEA SSS SAM L6
L8              STRUCTURE UPLOADED
L9            2 SEA SSS SAM L8

     FILE 'LREGISTRY' ENTERED AT 10:21:42 ON 05 JUN 2007
L10           0 SEA SSS FUL L8

     FILE 'BEILSTEIN' ENTERED AT 10:22:14 ON 05 JUN 2007
L11           0 SEA SSS SAM L8
L12           0 SEA SSS FUL L8

     FILE 'REGISTRY' ENTERED AT 10:23:30 ON 05 JUN 2007
L13         278 SEA SSS FUL L8

     FILE 'CAPLUS' ENTERED AT 10:26:57 ON 05 JUN 2007
L14           3 SEA ABB=ON  PLU=ON  L13
L15         902 SEA ABB=ON  PLU=ON  SEKIGUCHI Y?/AU
L16          32 SEA ABB=ON  PLU=ON  KANUMA K?/AU
L17          21 SEA ABB=ON  PLU=ON  OMODERA K?/AU
L18          19 SEA ABB=ON  PLU=ON  BUSUJIMA T?/AU
L19        2458 SEA ABB=ON  PLU=ON  TRAN T?/AU
L20        9406 SEA ABB=ON  PLU=ON  HAN S?/AU
L21          54 SEA ABB=ON  PLU=ON  CASPER M?/AU
L22         757 SEA ABB=ON  PLU=ON  KRAMER B?/AU
L23          92 SEA ABB=ON  PLU=ON  SEMPLE G?/AU
L24          95 SEA ABB=ON  PLU=ON  ZOU N?/AU
L25           3 SEA ABB=ON  PLU=ON  (L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR
                L21 OR L22 OR L23 OR L24) AND L14

     FILE 'MARPAT' ENTERED AT 10:36:37 ON 05 JUN 2007
L26           1 SEA SSS SAM L8
L27          24 SEA SSS FUL L8

     FILE 'CAPLUS' ENTERED AT 10:39:22 ON 05 JUN 2007
L28           0 SEA ABB=ON  PLU=ON  L14 NOT L25

     FILE 'MARPAT' ENTERED AT 10:40:40 ON 05 JUN 2007
L29          24 SEA ABB=ON  PLU=ON  L27 NOT L25

=>
```